MRC WORKSHOP ON DOSE-FINDING METHODOLOGY IN EARLY PHASE CLINICAL TRIALS
Programme and Speakers

Day One

Bayesian Modelling for Phase I Cancer Trials

9.00  Registration
9.30  Welcome: Dr. D.S. Coad (Queen Mary, University of London)
9.45  Keynote lecture: Professor J. O’Quigley (French National Institute for Health and Medical Research)

Bayesian model choice for generalized CRM models

10.45  Coffee break
11.15  Speaker one: Dr. A. Iasonos (Memorial Sloan Kettering Center)

Estimating the dose-toxicity curve in completed phase I studies

12.00  Speaker two: Professor K. Cheung (Columbia University)

Specification of a CRM model

12.45  Lunch
2.15  Speaker three: Dr. F. Vandenhende (ClinBAY, Belgium)

Adaptive decision strategy in early phase

3.00  Speaker four: Dr. H. Siedentop (Bayer Schering Pharma AG, Germany)

Optimal phase I dose-escalation trial designs in oncology - a simulation study

3.45  Tea break
4.15  Discussion
4.45  Day one finishes
5.00  Poster/software demonstration session

Day Two

Combined Phase I/II Trials and Non-Cancer Studies

9.00  Registration
9.45  Keynote lecture: Professor J.R. Whitehead (University of Lancaster)

A Bayesian dose-escalation procedure for phase I clinical trials based only on the assumption of monotonicity

10.45  Coffee break
11.15  Speaker one: Dr. S. Zohar (French National Institute for Health and Medical Research)

Identifying the most successful dose under toxicity restrictions in phase I/II dose-finding studies

12.00  Speaker two: Dr. N. Benda (Federal Institute for Drugs and Medical Devices, Germany)

Adaptive dose-finding with an active comparator

12.45  Lunch
2.15  Speaker three: Professor B. Jones (Pfizer)

Choice of an adaptive Bayesian design for an early phase II dose-finding trial

3.00  Speaker four: Dr. F. Miller (AstraZeneca, Sweden)

Adaptive dose-finding designs in phase IIb

3.45  Tea break
4.15  Discussion
4.45  Day two finishes
Day Three

Bayesian versus Non-Bayesian Adaptive Designs

9.00 Registration
9.45 Keynote lecture: Professor A.P. Grieve (King’s College London)
   Title to be announced
10.45 Coffee break
11.15 Speaker one: Professor D. Ashby (Imperial College London)
   Incorporating prior information in design of Bayesian dose-finding studies
   using one-stage and two-stage models
12.00 Speaker two: Professor A. Ivanova (University of North Carolina)
   Dose-finding methods for phase II trials
12.45 Lunch
2.15 Speaker three: Dr. D. Austin (GlaxoSmithKline)
   Title to be announced
3.00 Speaker four: Mr. R. Hemmings (MHRA)
   Regulatory position on the use of adaptive designs in exploratory drug development
3.45 Tea break
4.15 Speaker five: Dr. A. Mander (MRC Biostatistics Unit)
   H1-optimal two-stage designs
4.45 Discussion
5.15 Day three finishes